早期大剂量维生素D3用于重症维生素D缺乏患者
VIOLET试验为随机、双盲、安慰剂对照3期试验,纳入重症且维生素D缺乏、死亡高风险患者,在决定收住ICU后12小时内随机给予单次肠内维生素D3 540,000 IU或匹配安慰剂。共1360例筛查缺乏者随机,1078例经后续检测确认基线25-羟基维生素D<20 ng/mL者纳入主分析。第3天25-羟基维生素D均值维生素D组46.9±23.2 ng/mL vs 安慰剂组11.4±5.6 ng/mL(差值35.5 ng/mL,95%CI 31.5–39.6)。90天死亡率维生素D组23.5%(125/531)vs 安慰剂组20.6%(109/528)(差值2.9个百分点,95%CI -2.1至7.9,P=0.26)。次要临床、生理或安全性终点两组无临床重要差异,基线维生素D缺乏严重程度不影响治疗与死亡率的关联。
要点
- 重症维生素D缺乏患者早期单次肠内54万IU维生素D3,90天死亡率23.5% vs 安慰剂20.6%,差值2.9个百分点(95%CI -2.1至7.9,P=0.26),未达统计学显著。
- 第3天25-羟基维生素D均值维生素D组46.9±23.2 ng/mL vs 安慰剂组11.4±5.6 ng/mL,差值35.5 ng/mL(95%CI 31.5–39.6),提示肠内大剂量可显著提升血浓度。
- 两组次要临床、生理或安全性终点无临床重要差异。
- 基线维生素D缺乏严重程度不影响治疗分配与死亡率之间的关联。
- 随机化在决定收住ICU后12小时内完成,干预为单次肠内给药。
适用人群与场景
- 重症、维生素D缺乏且死亡高风险的成人患者,在决定收住ICU后12小时内随机。
- 主分析人群为经后续检测确认基线25-羟基维生素D<20 ng/mL(50 nmol/L)者,共1078例。
诊断标准与关键阈值
- 维生素D缺乏定义:25-羟基维生素D<20 ng/mL(50 nmol/L)。
- 纳入需在决定收住ICU后12小时内完成随机化。
处置流程与药物剂量
- 单次肠内给予维生素D3 540,000 IU或匹配安慰剂。
- 随机化在决定收住ICU后12小时内进行。
研究设计与关键结果
- 随机、双盲、安慰剂对照3期试验;1360例筛查缺乏者随机,1078例确认基线25-羟基维生素D<20 ng/mL者纳入主分析。
- 第3天25-羟基维生素D均值:维生素D组46.9±23.2 ng/mL(117±58 nmol/L)vs 安慰剂组11.4±5.6 ng/mL(28±14 nmol/L),差值35.5 ng/mL(95%CI 31.5–39.6)。
- 90天死亡率:维生素D组23.5%(125/531)vs 安慰剂组20.6%(109/528),差值2.9个百分点(95%CI -2.1至7.9,P=0.26),未达统计学显著。
- 两组次要临床、生理或安全性终点无临床重要差异。
- 基线维生素D缺乏严重程度不影响治疗分配与死亡率之间的关联。
证据类型、等级与局限
- 证据类型:随机、双盲、安慰剂对照3期试验(VIOLET,NCT03096314)。
- 由美国国家心肺血液研究所资助。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于重症维生素D缺乏患者,早期单次肠内大剂量维生素D3未显示较安慰剂改善90天死亡率或其他非致死性结局,不支持以此为常规做法。
- 尽管第3天25-羟基维生素D水平显著升高,但未转化为死亡率获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Vitamin D deficiency is a common, potentially reversible contributor to morbidity and mortality among critically ill patients. The potential benefits of vitamin D supplementation in acute critical illness require further study.
METHODS: We conducted a randomized, double-blind, placebo-controlled, phase 3 trial of early vitamin D3 supplementation in critically ill, vitamin D-deficient patients who were at high risk for death. Randomization occurred within 12 hours after the decision to admit the patient to an intensive care unit. Eligible patients received a single enteral dose of 540,000 IU of vitamin D3 or matched placebo. The primary end point was 90-day all-cause, all-location mortality.
RESULTS: A total of 1360 patients were found to be vitamin D-deficient during point-of-care screening and underwent randomization. Of these patients, 1078 had baseline vitamin D deficiency (25-hydroxyvitamin D level, <20 ng per milliliter [50 nmol per liter]) confirmed by subsequent testing and were included in the primary analysis population. The mean day 3 level of 25-hydroxyvitamin D was 46.9±23.2 ng per milliliter (117±58 nmol per liter) in the vitamin D group and 11.4±5.6 ng per milliliter (28±14 nmol per liter) in the placebo group (difference, 35.5 ng per milliliter; 95% confidence interval [CI], 31.5 to 39.6). The 90-day mortality was 23.5% in the vitamin D group (125 of 531 patients) and 20.6% in the placebo group (109 of 528 patients) (difference, 2.9 percentage points; 95% CI, -2.1 to 7.9; P = 0.26). There were no clinically important differences between the groups with respect to secondary clinical, physiological, or safety end points. The severity of vitamin D deficiency at baseline did not affect the association between the treatment assignment and mortality.
CONCLUSIONS: Early administration of high-dose enteral vitamin D3 did not provide an advantage over placebo with respect to 90-day mortality or other, nonfatal outcomes among critically ill, vitamin D-deficient patients. (Funded by the National Heart, Lung, and Blood Institute; VIOLET ClinicalTrials.gov number, NCT03096314.).
参考来源
- Ginde AA, Brower RG, Caterino JM, et al. Early High-Dose Vitamin D3 for Critically Ill, Vitamin D-Deficient Patients. N Engl J Med. 2019. PMID: 31826336. doi:10.1056/NEJMoa1911124
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。